^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Junction Adenocarcinoma

    Related cancers:
    1d
    Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer. (PubMed, Discov Oncol)
    Clinicopathological characteristics and baseline peripheral lymphocyte subsets were significantly associated with efficacy of first-line chemotherapy combined with ICIs in pMMR HER2-negative advanced G/GEJC, highlighting the potential utility of integrating these accessible parameters for efficacy prediction.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    2d
    Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (clinicaltrials.gov)
    P1, N=48, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    CCNE1 (Cyclin E1)
    |
    HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • azenosertib (ZN-c3)
    2d
    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=168, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)
    2d
    NRG-GI007: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, NRG Oncology | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    carboplatin • paclitaxel • Telomelysin (suratadenoturev)
    2d
    FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=83, Recruiting, Axcynsis Therapeutics Pte Ltd | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • CLDN6 (Claudin 6)
    |
    EGFR mutation
    3d
    A Phase II Exploratory Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination with Bevacizumab for Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Open-Label, Multicenter Clinical Trial (ChiCTR2500108816)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical UniversitynThe First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliate | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    3d
    Clinical Efficacy of Pucotenlimab Combined with Lenvatinib and SOX Versus SOX Alone in Patients with HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Center Randomized Controlled Trial (ChiCTR2600116583)
    P=N/A, N=100, Not yet recruiting, Department of Gastric Surgery, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lenvima (lenvatinib) • oxaliplatin • Puyouheng (pucotenlimab)
    3d
    Neoadjuvant therapy with iparolituoworili combined with SOX chemotherapy regimen for locally advanced gastric/gastroesophageal junction adenocarcinoma: A prospective, multicenter, phase II, open-label, single-arm study. (ChiCTR2500115746)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    3d
    A Phase II Clinical Trial of PD-L1 Expression-Based Epaploitovorilimab Combined with Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Single-Arm, Open-Label (ChiCTR2500115675)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    oxaliplatin
    3d
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer with Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS) (ChiCTR2500114284)
    P=N/A, N=90, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    3d
    Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma (ChiCTR2500113343)
    P=N/A, N=55, Not yet recruiting, Zhongshan Hospital, Fudan Univeristy; Zhongshan Hospital, Fudan Univeristy
    New trial
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    3d
    Machine Learning-Driven Biomarker for Predicting Lymph Node Metastasis and Prognosis in Esophagogastric Junction Adenocarcinoma (ChiCTR2500112823)
    P=N/A, N=130, Recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial